PATRICIA ALTAVILLA APPOINTED AS CHIEF EXECUTIVE OFFICER AT SUNEVA MEDICAL

Company Advances into Next Phase of Regenerative Aesthetics with Industry Veteran

March 5, 2019 (San Diego, CA) – Suneva® Medical, Inc., privately held aesthetics company, announces Chief Executive Officer, Patricia Altavilla as successor to Preston Romm.

With over 30 years’ experience in the aesthetics and medical fields. Altavilla began her career at Mentor Corporation, serving as Vice President of International Sales and Worldwide Marketing. For nearly 20 years, she helped grow the company’s sales tenfold, launched new products and enhanced its global market presence by managing international direct and distributor relations. She then went on to be Vice President of Sales, Marketing and Operations at The Plastic Surgery Company, where she co-founded and ran Spa Medicus/Medicus Skin Enhancement for several years. Soon after, she joined BioForm Medical, now part of Merz Aesthetics, as the Vice President of Global Marketing, and was instrumental in restructuring the marketing department, growing sales, creating a practice development program and raising the company’s overall visibility in the marketplace that resulted in an acquisition by Merz Aesthetics. Altavilla also held numerous leadership roles at medical technology company ZELTIQ® Aesthetics Inc.

Throughout her career she has been instrumental in developing global marketing strategies, building physician loyalty, enhancing practice development, launching innovative products, and increasing the company’s industry presence. She has consistently led negotiations for joint ventures, strategic partnerships and distribution relationships in an effort to continue to advance the companies’ positions in the market place.

“As we redefine Suneva Medical’s position within the industry as leaders in Regenerative Aesthetics, I am honored to help pave the way for the company, further shaping the future of our brand,” said Altavilla. “With our introduction of two new products and continuing to build the success of our flagship product Bellafill, it is an exciting time for Suneva Medical.”

About Suneva Medical, Inc.

Suneva Medical is a privately‐held aesthetics company focused on developing, manufacturing and commercializing novel, differentiated products for the aesthetic markets. The innovative aesthetics leader markets Bellafill®, the only dermal filler on the market that is approved by the U.S. Food and Drug Administration for the correction of nasolabial folds and moderate to severe, atrophic, distensible facial acne scars on the cheek in patients over the age of 21 years old. The company markets Bellafill® in the U.S., Canada, Hong Kong, Korea and Mexico. For more information, visit www.sunevamedical.com.

Important Safety Information

Bellafill®
Bellafill® is indicated for the correction of nasolabial folds and moderate to severe, atrophic, distensible facial acne scars on the cheek in patients over the age of 21 years. Patients who have had a positive reaction to the Bellafill® Skin Test, have a history of severe allergies, have known bovine collagen allergies, are allergic to lidocaine, have bleeding disorders or are prone to thick scar formation and/or excessive scarring should not receive Bellafill®. The safety of Bellafill® for use during pregnancy, breastfeeding, or in patients under 21 has not been established. You may experience temporary swelling, redness, pain, bruising, lumps/bumps, itching, and discoloration at the treatment site. These side effects are usually transient and typically resolve within 1–7 days. You may experience lumps/bumps/papules that may occur more than one month after injection and that may persist. Less common side effects include rash and itching more than 48 hours after treatment, persistent swelling or redness, lumps/bumps, acne, and increased sensitivity at treatment sites. Infrequently, granulomas may occur and may be treated by your licensed physician provider. Be sure to call your licensed provider immediately if you notice any unusual skin reactions around the treatment area. Based on the 5-year Post-Approval Study on nasolabial folds with 1,008 patients, long-term safety of Bellafill® for up to 5 years has been established.

PUREGRAFT
This product is certified as a medical device in the European Union under the Medical Device Directive 93/42/EEC by SGS CE0120, exclusively for the indication of autologous fat transfer. Other non-medical uses ascribed to this device such as aesthetic body contouring are not within the scope of CE certification, and users should be aware product performance and/or safety has not been evaluated by SGS for those purposes.

Suneva Medical HD PRP
REGULATORY STATUS: FDA-cleared 510(k) Class II medical device. Healeon HD PRP is designed to be used for the safe and rapid preparation of autologous platelet-rich-plasma (PRP) from a small sample of peripheral blood at the patient point of care. The PRP is mixed with autograft and/orallograft bone prior to application to a bony defect for improving handling characteristics. 510(k) number: BK170136

For more safety information, please consult with your physician and the patient labeling that can be found by visiting our website www.bellafill.com.
Toll-free call (U.S. & Canada): 844-Bellafill (844-235-5234).
Local calls: 858-550-9999. International calls: ++ 858-550-9999.